Neumora Therapeutics Stock News

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology

NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction  NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide Class-leading weight loss driven by best-in-class pharmacology and brain penetration of NMRA-215 Neumora plans to initiate Phase 1 clinical study in the first quarter of 2026 WATERTOWN, Mass., ...

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will host a virtual R&D Day on Monday, October 27, 2025, at 8:00 a.m.

WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in three investor conferences in September.

Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Daljit Singh Aurora - Corporate Participant Chief Operationg & Development officer - Corporate Participant Helen Rubinstein - Head of Investor Relations Joshua Pinto - President Michael Lee Milligan - CFO & Principal Accounting Officer Nicholas Brandon - Chief Scientific Off...

Neumora Therapeutics (NMRA -4.22%), a clinical-stage neuroscience company developing targeted therapies for brain diseases, released its second quarter 2025 results on August 6, 2025. The most significant news was a reduction in both research and development spending and overall net loss, while the company advanced multiple programs in its clinical pipeline.

Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with data from diet-induced obesity (DIO) mouse model expected in 2025 Entering catalyst-rich period wit...

WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, August 6, 2025 to report its second quarter 202...